Kidney Health Initiative (KHI)

At a Glance
  • Status: Active Consortium
  • Year Launched: 2013
  • Initiating Organization: American Society of Nephrology
  • Initiator Type: Third-party organization
  • Disease focus:
    Renal Failure
  • Location: North America


The goal of the Kidney Health Initiative (KHI) is to advance scientific understanding of the kidney health and patient safety implications of new and existing medical products and to foster development of therapies for diseases that affect the kidney by creating a collaborative environment in which the U.S. Food and Drug Administration (FDA) and the greater nephrology community can interact to optimize evaluation of drugs, devices, biologics, and food products. This consortium is managed by the American Society of Nephrology.


KHI is a consortium that brings together the kidney community (i.e., patient advocacy groups, industry, government agencies, and professional organizations) to overcome existing challenges, including regulatory and nonregulatory barriers and to optimize the development and safety of products that impact kidney health.

KHI’s goals are as follows:

Consortium History

March 2012: The American Society of Nephrology (ASN) expressed concerns to FDA about stagnancy in product development related to kidney health and the safety of other products with the potential to impact kidney health. Representatives from FDA and ASN met to discuss their shared interest in optimizing efforts to address public health issues related to kidney health. Although several options were discussed, the public-private partnership model was deemed especially attractive given the successes of previous such efforts. Both parties noted that the partnership model provides continuity and sustainability — critical elements of an effort intended to transform a sector of medicine as opposed to simply fix an isolated issue.

Structure & Governance

The KHI Board of Directors represents the diversity of stakeholders in the kidney community and includes representation from other federal agencies, including the Agency for Healthcare Research and Quality, Centers for Medicare & Medicaid Services, and National Institutes of Health. KHI is cochaired by an ASN representative and an FDA physician.

Member organizations can submit project concepts as long as they aim to improve safety or foster innovation.  Project ideas are evaluated by the KHI cochairs and the Board to ensure all the selected projects are strongly aligned with KHI’s overall mission, efficiently leverage KHI resources, and have a well-defined strategy for execution.

After project concepts are finalized and endorsed by the Board, KHI will post a work group opportunity so that all members may apply to participate. The final composition of the work group will be determined by the Board after review of the applications; the Board will make its work group selections after assessing the applicant’s professional qualifications, willingness to dedicate protected time to the project, and manageability of any potential conflicts of interest.


KHI received seed funding from FDA ($2.5 million) in the form of a formal public-private partnership with ASN. Member organizations pay an annual fee based on their size. Fees primarily support KHI’s operational cost. It is also anticipated that KHI could, in future years, consider seeking competitive grant funding to support specific projects from private or public entities.

Data Sharing

Specific details were not available. As a principle, KHI encourages researchers to not enter into agreements that interfere with their access to all of the data and/or their ability to analyze them independently, and to prepare and publish manuscripts. Authors should describe the role of the study sponsor, if any, in study design; collection, analysis, and interpretation of data; writing the report; and the decision to submit the report for publication. If the supporting source had no such involvement, then the authors should so state.

Several patient organizations are founding members of KHI, including the American Association of Kidney Patients, NephCure Foundation, Renal Support Network, PKD Foundation, and National Kidney Foundation.

Sponsors & Partners


American Association of Kidney Patients

American College of Clinical Pharmacy

American Nephrology Nurses’ Association

American Society for Apheresis

American Society of Diagnostic and Interventional Nephrology

American Society of Nephrology

American Society of Pediatric Nephrology

American Society of Transplantation

Amgen, Inc.

Anthera Pharmaceuticals, Inc.

Arbor Research Collaborative for Health

Association for the Advancement of Medical Instrumentation



Binding Site, Inc.

Boehringer Ingelheim

C.R. Bard, Inc.

ChemoCentryx Inc.

Clinical Metabolomics Inc. (d/b/a ClinMet)

DaVita, Inc.

Dialysis Clinic, Inc.

Dialysis Patient Citizens

Duke Clinical Research Institute

Eli Lilly and Company

European Renal Association-European Dialysis & Transplant Association

FAST BioMedical

Fibrotech Therapeutics Pty Ltd.

Fresenius Medical Care

George Institute

Home Dialyzors United

Hospira, Inc.

Institute Kidney Foundation of Delhi

JDRF International

Karolinska Institutet

MediBeacon, LLC

Medtronic, Inc.

National Kidney Foundation

National Renal Administrators Association

NephCure Foundation

Nephrology Nursing Certification Commission

NxStage Medical, Inc.

OPKO Health, Inc.

Otsuka America Pharmaceutical, Inc.

PeaceHealth Dialysis Center

Pfizer, Inc.

PKD Foundation

Proteon Therapeutics, Inc.

Puracath Medical

Questcor Pharmaceuticals Inc.

Quintiles Global Clinical Research Organization

Reata Pharmaceuticals

Relypsa, Inc.

Renal Physicians Association

Renal Support Network

Rockwell Medical Inc.

Sanofi S.A.

St. Marianna University School of Medicine

Thrasos Innovation, Inc.

University of Oxford

University of Tokyo Hospital

University of Washington

U.S. Food and Drug Administration

Vascular Access Society

Vascular Therapies

Vasculitis Foundation

W.L. Gore & Associates

Last Updated: 10/10/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.